Comparison of the chronic effects of ribavirin and caffeic acid phenethyl ester (CAPE) on pancreatic damage and hepatotoxicity

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 4, 2014, Pages 1005-1013

  Motor, Sedat ^a   Alp, Harun ^a   Şenol, Serkan ^b   Pinar, Neslihan ^a   Motor, Vicdan Köksaldi ^a   Kaplan, Ibrahim ^c   Alp, Ayşe ^d   Gökçe, Cumali ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b Medeniyet University   (Turkey)

^c DICLE UNIVERSITY   (Turkey)

^d Department of Infectious Diseases and Clinical Microbiology School of Medicine Mustafa Kemal University ^*  (Turkey)

Author keywords

CAPE; Hepatotoxicity; Insulin; Oxidative stress; Pancreatic damage; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CAFFEIC ACID PHENETHYL ESTER; INSULIN; RIBAVIRIN; TRIACYLGLYCEROL LIPASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ASSAY; ARTICLE; BIOCHEMISTRY; CELL DEATH; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; INFLAMMATION; LIVER TOXICITY; NONHUMAN; PANCREAS INJURY; RAT;

EID: 84900411591     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, Ten Eyck LG and Hall WJ. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983; 308: 1443-1447.
2. Fang C, Srivastava P and Lin CC. Effect of ribavirin, levovirin and viramidine on liver toxicological gene expression in rats. J Appl Toxicol 2003; 23: 453-459.
3. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A and Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-87.
4. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT and Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177: 705-706.
5. Patterson JL and Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1139-1146.
6. Milicevic I, Pekovic S, Subasic S, Mostarica-Stojkovic M, Stosic-Grujicic S, Medic-Mijacevic L, Pejanovic V, Rakic L and Stojiljkovic M. Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. J Neurosci Res 2003; 72: 268-278.
7. Peavy DL, Koff WC, Hyman DS and Knight V. Inhibition of lymphocyte proliferative responses by ribavirin. Infect Immun 1980; 29: 583-589.
8. Heagy W, Crumpacker C, Lopez PA and Finberg RW. Inhibition of immune functions by antiviral drugs. J Clin Invest 1991; 87: 1916-1924.
9. Alp H, Aytekin I, Esen H, Başarili K and Kul S. Effects of Caffeic Acid Phenethyl Ester, Ellagic Acid, Sulforaphane and Curcumin on Diazinon Induced Damage to the Lungs, Liver and Kidneys in An Acute Toxicity Rat Model. Kafkas Univ Vet Fak Derg 2011; 17: 927-933.
10. Alp A, Buyukbas S, Alp H, Gergerlioglu HS, Oz M, Basarali MK and Kiyici A. Effects of exercise and caffeic acid phenethyl ester after chronic exercise rat model. J Sports Sci Med 2011; 10: 649-654.
11. Tomur A, Kanter M, Gurel A and Erboga M. The efficiency of CAPE on retardation of hepatic fibrosis in biliary obstructed rats. J Mol Histol 2011; 42: 451-458.
12. Albukhari AA, Gashlan HM, El-Beshbishy HA, Nagy AA and Abdel-Naim AB. Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats. Food Chem Toxicol 2009; 47: 1689-1695.
13. Saavedra-Lopes M, Ramalho FS, Ramalho LN, Andrade-Silva A, Martinelli AL, Jordao AA Jr, Castro-e-Silva O and Zucoloto S. The protective effect of CAPE on hepatic ischemia/reperfusion injury in rats. J Surg Res 2008; 150: 271-277.
14. Gokcimen A, Cim A, Tola HT, Bayram D, Kocak A, Ozguner F and Ayata A. Protective effect of N-acetylcysteine, caffeic acid and vitamin E on doxorubicin hepatotoxicity. Hum Exp Toxicol 2007; 26: 519-525.
15. Kus I, Colakoglu N, Pekmez H, Seckin D, Ogeturk M Sarsilmaz M. Protective effects of caffeic acid phenethyl ester (CAPE) on carbon tetrachloride-induced hepatotoxicity in rats. Acta Histochem 2004; 106: 289-297.
16. Lee KJ, Choi JH, Khanal T, Hwang YP, Chung YC and Jeong HG. Protective effect of caffeic acid phenethyl ester against carbon tetrachloride-induced hepatotoxicity in mice. Toxicology 2008; 248: 18-24.
17. Koyu A, Gokalp O, Gumral N, Oktem F, Karahan N, Yilmaz N and Saygin M. Impact of caffeic acid phenethyl ester treatment on vancomycin-induced pancreatic damage in rats. Toxicol Ind Health 2013; [Epub ahead of print].
18. Turkyilmaz S, Alhan E, Ercin C, Kural Vanizor B, Kaklikkaya N, Ates B, Erdogan S and Topaloglu S. Effects of caffeic acid phenethyl ester on pancreatitis in rats. J Surg Res 2008; 145: 19-24.
19. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-1111.
20. Onur OE, Guneysel O, Akoglu H, Denizbasi A and Onur E. Adrenomedullin reduces the severity of cerulein-induced acute pancreatitis. Peptides 2007; 28: 2179-2183.
21. Virlos I, Mazzon E, Serraino I, Di Paola R, Genovese T, Britti D, Thiemerman C, Siriwardena A and Cuzzocrea S. Pyrrolidine dithiocarbamate reduces the severity of cerulein-induced murine acute pancreatitis. Shock 2003; 20: 544-550.
22. Kesik V, Guven A, Vurucu S, Tunc T, Uysal B, Gundogdu G, Oztas E and Korkmaz A. Melatonin and 1400 W ameliorate both intestinal and remote organ injury following mesenteric ischemia/reperfusion. J Surg Res 2009; 157: e97-e105.
23. Snell NJ. Ribavirin--current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001; 2: 1317-1324.
24. Fernandez H, Banks G and Smith R. Ribavirin: a clinical overview. Eur J Epidemiol 1986; 2: 1-14.
25. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH and Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314: 20-26.
26. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989; 11 Suppl 4: S750-761.
27. World Health Organization (WHO). The Secretary of the Expert Committee on the Selection and Use of Essential Medicines Policy, Access and Rational Use Department of Medicines Policy and Standards. 20 Avenue Appia CH-1211 Geneva 27, Ribavirin.doc. 1/31 pp. Switzerland email: emlsecretariat@who.int. 07 Nov. 06.
28. Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, Ksiazek TG, Koster FT, Baum KF, Rollin PE, Pavia AT, Holman RC, Christenson JC, Rubin PJ, Behrman RE, Bell LJ, Simpson GL and Sadek RF. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 1999; 4: 211-219.
29. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P and Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287: 2391-2405.
30. Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res 2005; 107: 165-171.
31. Abdel Salam OM, Sleem AA, Omara EA and Hassan NS. Effect of ribavirin alone or combined with silymarin on carbon tetrachloride induced hepatic damage in rats. Drug Target Insights 2007; 2: 19-27.
32. Quadri R, Giostra E, Roskams T, Pawlotsky JM, Mentha G, Rubbia-Brandt L, Perrin L, Hadengue A and Negro F. Immunological and virological effects of ribavirin in hepatitis C after liver transplantation. Transplantation 2002; 73: 373-378.
33. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K and Hoofnagle JH. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.
34. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, Phillips MJ and Levy G. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160: 3487-3493.
35. Cattral MS, Hemming AW, Wanless IR, Al-Ashgar H, Krajden M, Lilly L, Greig PD and Levy GA. Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 1999; 67: 1277-1280.
36. Stanimirovic V, Nikolic D, Stanimirovic B, Nikolic A and Cucak S. Evaluation of ribavirin efficacy and tolerance in subjects with chronic hepatitis C virus infection. Vojnosanit Pregl 2002; 59: 479-484.
37. Hoofnagle JH, Ghany MG, Kleiner DE, Doo E, Heller T, Promrat K, Ong J, Khokhar F, Soza A, Herion D, Park Y, Everhart JE and Liang TJ. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003; 38: 66-74.
38. Chaudhari S, Park J, Anand BS, Pimstone NR, Dieterich DT, Batash S and Bini EJ. Acute pancreatitis associated with interferon and ribavirin therapy in patients with chronic hepatitis C. Dig Dis Sci 2004; 49: 1000-1006.
39. Bliss M. The Discovery of Insulin. Chicago: University of Chicago Press, 2007.
40. Kurcer Z, Karaoglu D. The use of Alloxan and Streptozotocin in Experimental Diabetes Models. Turk Jem 2012; 16: 34-40.
41. Levent G, Ali A, Ahmet A, Polat EC, Aytac C, Ayse E and Ahmet S. Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy. J Transl Med 2006; 4: 25.